BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 12, 2008
 |  BioCentury  |  Product Development

Eye of the beholder

Novartis AG says its Menveo quadrivalent meningitis vaccine showed a superior immune response in a head-to-head study vs. Menactra from sanofi-aventis Group. But the French pharma says it's impossible to discern a meaningful difference because the study was designed to show non-inferiority.

FDA approved Menactra in 2005 to protect against meningococcal disease in adolescents and adults aged 11-55 years. Last year, the label was expanded to include children ages 2-10. The vaccine posted 2007 net sales of E415 million ($642.5 million).

Both products are quadrivalent polysaccharide vaccines against serotypes A, C, W-135 and Y. But while Menactra uses a diphtheria toxoid as the carrier protein, Menveo uses CRM-197 carrier protein, which is a non-toxic variant of diphtheria toxin.

"Conceptually, both Menactra and Menveo are essentially the same: polysaccharide that is coupled to a carrier protein," said Joerg Reinhart, CEO of the Novartis Vaccines unit. "The difference is the carrier protein, which is the...

Read the full 765 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >